Email this article 
Hide
Show all
Original Research
Agreement between Xpert and AmpFire tests for high-risk human papillomavirus among HIV-positive women in Rwanda
Submitted: 06 January 2022 | Published: 19 October 2022
About the author(s)
Anthere Murangwa, Rwanda Military Hospital, Kigali, RwandaKanan T. Desai, Division of Cancer Epidemiology & Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, United States
Julia C. Gage, Division of Cancer Epidemiology & Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, United States
Gad Murenzi, Rwanda Military Hospital, Kigali, Rwanda
Patrick Tuyisenge, Rwanda Military Hospital, Kigali, Rwanda
Faustin Kanyabwisha, Rwanda Military Hospital, Kigali, Rwanda
Aimable Musafili, Department of Paediatrics and Child Health, School of Medicine and Pharmacy, College of Medicine and Health Sciences, University of Rwanda, Kigali, Rwanda
Gallican Kubwimana, Rwanda Military Hospital, Kigali, Rwanda; and, Research for Development (RD Rwanda), Kigali, Rwanda
Leon Mutesa, Research for Development (RD Rwanda), Kigali, Rwanda; and, Centre for Human Genetics, College of Medicine and Health Sciences, University of Rwanda, Kigali, Rwanda
Kathryn Anastos, Departments of Medicine and Epidemiology & Population Health, Albert Einstein College of Medicine and Montefiore Health Systems, Bronx, New York, United States
Hae-Young Kim, Department of Public Health, New York Medical College, Valhalla, New York, United States
Philip E. Castle, Division of Cancer Epidemiology & Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, United States; and, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Rockville, Maryland, United States
Abstract
Background: High-risk human papillomavirus (hrHPV) may cause more than 99% of cervical cancers worldwide. Little is known about performance differences in tests for hrHPV.
Objective: This study analysed agreement for detection of hrHPV between the established, clinically validated Xpert HPV assay and the novel isothermal amplification-based AmpFire HPV genotyping assay.
Methods: This study was nested in a larger project on cervical cancer screening among approximately 5000 women living with HIV in Kigali, Rwanda. This sub-study included 298 participants who underwent initial screening for cervical cancer using the Xpert HPV assay and visual inspection with acetic acid in 2017 and tested positive by either or both. Participants were rescreened using colposcopy, and cervical samples were collected between June 2018 and June 2019. Samples were then tested for HPV using the Xpert HPV assay and AmpFire HPV genotyping assay. Agreement between results from both tests was analysed using an exact version of McNemar test and chi-square test.
Results: Overall agreement and kappa value for detection of hrHPV by Xpert and AmpFire were 89% and 0.77 (95% confidence interval: 0.70–0.85). AmpFire was marginally more likely to diagnose hrHPV-positive than Xpert (p = 0.05), due primarily to the extra positivity for HPV16 (p < 0.001).
Conclusion: Overall, there was good to excellent agreement between the Xpert and AmpFire when testing hrHPV types among women living with HIV. AmpFire was more likely to test extra cases of HPV16, the most carcinogenic HPV type, but the clinical meaning of detecting additional HPV16 infections remains unknown.
Keywords
Metrics
Total abstract views: 4087Total article views: 3818
Crossref Citations
1. Comparison of the AmpFire and MA-6000 polymerase chain reaction platforms for high-risk human papillomavirus testing in cervical precancer screening
Kofi Effah, Isaac Agbemafle, Nana Owusu Essel, Joseph Emmanuel Amuah, Erasmus Nikoi Kotey, Ernest Antwi-Boasiako, Seyram Kemawor, Isaac Gedzah, Ethel Tekpor, Comfort Mawusi Wormenor, Bernard Hayford Atuguba, Stephen Danyo, Patrick Kafui Akakpo
Journal of Virological Methods vol: 316 first page: 114709 year: 2023
doi: 10.1016/j.jviromet.2023.114709
2. Comparison of the ScreenFire and Xpert HPV assays for the detection of human papillomavirus and cervical precancer among women living with HIV in Malawi
Chemtai Mungo, Anagha Guliam, Lameck Chinula, Federica Inturrisi, Lizzie Msowoya, Tawonga Mkochi, Siniya Jawadu, Silvia de Sanjosé, Mark Schiffman, Jennifer H. Tang, Jennifer S. Smith
Infectious Agents and Cancer vol: 19 issue: 1 year: 2024
doi: 10.1186/s13027-024-00585-4
3. Building health research capacity in Africa: the Einstein-Rwanda research and capacity building program
Gad Murenzi, Gallican Kubwimana, Fidel Rubagumya, Pacifique Mugenzi, Alex Buteera, Emmanuel Rudakemwa, Jonathan Ross, Tiffany Hebert, Adebola Adedimeji, Sabin Nsanzimana, Marcel Yotebieng, Joel Palefsky, Leon Mutesa, Philip E. Castle, Kathryn Anastos
BMC Global and Public Health vol: 3 issue: 1 year: 2025
doi: 10.1186/s44263-025-00134-0
4. Comparison of the AmpFire® Multiplex HPV Assay to the Xpert® HPV Assay for detection of human papillomavirus and cervical disease in women with human immunodeficiency virus: a pragmatic performance evaluation
Sikhulile Moyo, Doreen Ramogola-Masire, Natasha O. Moraka, Leabaneng Tawe, Farzad Noubary, Kesego Motsumi, Godiraone Manowe, Boitumelo Zuze, Botshelo Radibe, Faith T. T. Hungwe, Terence Mohammed, Comfort Maphorisa, Roger Shapiro, Simani Gaseitsiwe, Rebecca Luckett
Infectious Agents and Cancer vol: 18 issue: 1 year: 2023
doi: 10.1186/s13027-023-00504-z
5. Evaluating the performance of the Xpert HPV assay in detecting HPV positive cases in Morocco
Said Ali Yerim, Youssef Chami Khazraji, Rachid Bekkali, Maria Bennai, Nassiba Bahra, Imane Chaoui, Fatima Zahra Chellat, Zineb Gaizi, Nabil Tachfouti, Anas Benabdellah, Bouchra Belkadi, Mohammed Attaleb, Mohamed Amine Berraho, Mohammed El Mzibri
Tumour Virus Research vol: 19 first page: 200318 year: 2025
doi: 10.1016/j.tvr.2025.200318
6. Evaluating operational parameters of the careHPV, GeneXpert, AmpFire, and MA-6000 HPV systems for cervical precancer screening: Experience from Battor, Ghana
Kofi Effah, Comfort Mawusi Wormenor, Ethel Tekpor, Joseph Emmanuel Amuah, Nana Owusu M. Essel, Isaac Gedzah, Seyram Kemawor, Benjamin Tetteh Hansen, Bernard Hayford Atuguba, Gifty Belinda Klutsey, Edna Sesenu, Stephen Danyo, Patrick Kafui Akakpo, Natalia M. Rodriguez
PLOS Global Public Health vol: 3 issue: 8 first page: e0001639 year: 2023
doi: 10.1371/journal.pgph.0001639